Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 20;25(1):314.
doi: 10.1186/s12882-024-03745-1.

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes

Yiqi Qian  1 , Wei Wu  1 , Minmin Wang  2 , Yifan Wei  2 , Ming Zhong  3
Affiliations

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes

Yiqi Qian et al. BMC Nephrol. .

Abstract

We are writing to you in response to the article published in BMC Nephrology titled "Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study". The study provided valuable information on the use of nafamostat mesylate (NM) during continuous renal replacement therapy (CRRT) in critically ill patients. We noticed in this study that a higher dose of NM resulted in a decrease in ICU and hospital mortality. However, the underlying mechanism behind this phenomenon remains unclear. We believe exploring this further is warranted.

Keywords: Adsorption; Continuous renal replacement therapy; Filter membrane; Nafamostat mesylate.

PubMed Disclaimer

Conflict of interest statement

MZ is involved in a clinical research with Baxter Healthcare Corporation. This article is not supported by any company or funding. No other author has reported a potential conflict of interest relevant to this article.

Similar articles

See all similar articles

References

    1. Kameda S, et al. Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study. BMC Nephrol. 2024;25(1):69. - PMC - PubMed
    1. Goto S, et al. Differences in the adsorption of nafamostat mesilate between polyester-polymer alloy and polysulfone membranes. J Artif Organs. 2017;20(2):138–44. - PubMed
    1. Hirayama T, et al. AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study. J Intensive Care. 2017;5:46. - PMC - PubMed
    1. Nakamura Y, et al. Adsorption of Nafamostat Mesilate on AN69ST membranes: a single-Center Retrospective and in Vitro Study. Ther Apher Dial. 2017;21(6):620–7. - PubMed
    1. Doi K, et al. Associations of Polyethylenimine-Coated AN69ST membrane in continuous renal replacement therapy with the Intensive Care outcomes: observations from a Claims database from Japan. Blood Purif. 2017;44(3):184–92. - PMC - PubMed

LinkOut - more resources